TY - JOUR
T1 - An Evaluation of Diagnostic Yield From Bronchoscopy
T2 - The Impact of Clinical/Radiographic Factors, Procedure Type, and Degree of Suspicion for Cancer
AU - Silvestri, Gerard A.
AU - Bevill, Benjamin T.
AU - Huang, Jing
AU - Brooks, Mary
AU - Choi, Yoonha
AU - Kennedy, Giulia
AU - Lofaro, Lori
AU - Chen, Alex
AU - Rivera, M. Patricia
AU - Tanner, Nichole T.
AU - Vachani, Anil
AU - Yarmus, Lonny
AU - Pastis, Nicholas J.
N1 - Funding Information:
Author contributions: G. S. B. B. and N. P. had full access to all of the data in the study and take responsibility for the integrity and the accuracy of the data. All authors contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript. J. H. and Y. C. contributed substantially to statistical analysis. Financial/nonfinancial disclosures: The authors have reported to CHEST the following: G. A. S. has received research grant awards to his university from Olympus America, Auris Health, Inc. Veracyte, Inc. and Veran Medical, Inc.; and consulting fees from Olympus and Auris Health, Inc. J. H. Y. C. G. K. and L. L. are employees of Veracyte, Inc. M. P. R. receives funding from the National Institutes of Health/National Cancer Institute; is a member of the Biodesix Tech Medical and Scientific Advisory Board; and is Chair of the bioAffinity Tech Medical and Scientific Advisory Board. N. T. T. has received other grant funding (American Cancer Society), industry grant funding (Exact Sciences, Veracyte, Integrated Diagnostics, and Oncimmune), and consulting monies (Integrated Diagnostics, Olympus, Cook Medical, and OncoCyte); and has participated in advisory board meetings (Veracyte). A. V. has served on scientific advisory boards for Veracyte, Inc. and Johnson & Johnson; and has received research funding from Johnson & Johnson, MagArray, Inc. Intuitive Surgical, and Broncus Medical to support clinical research and enrollment into clinical trials. L. Y. is a consultant for Veracyte, Inc. N. J. P. has participated in consulting for Olympus related to new bronchoscope developments over the past 3 years. None declared (B. T. B. M. B. A. C.). Additional information: The e-Tables can be found in the Supplemental Materials section of the online article.
Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following: G. A. S. has received research grant awards to his university from Olympus America, Auris Health, Inc., Veracyte, Inc., and Veran Medical, Inc.; and consulting fees from Olympus and Auris Health, Inc. J. H., Y. C., G. K., and L. L. are employees of Veracyte, Inc. M. P. R. receives funding from the National Institutes of Health /National Cancer Institute; is a member of the Biodesix Tech Medical and Scientific Advisory Board; and is Chair of the bioAffinity Tech Medical and Scientific Advisory Board. N. T. T. has received other grant funding ( American Cancer Society ), industry grant funding (Exact Sciences, Veracyte, Integrated Diagnostics, and Oncimmune), and consulting monies (Integrated Diagnostics, Olympus, Cook Medical, and OncoCyte); and has participated in advisory board meetings (Veracyte). A. V. has served on scientific advisory boards for Veracyte, Inc. and Johnson & Johnson; and has received research funding from Johnson & Johnson , MagArray, Inc., Intuitive Surgical, and Broncus Medical to support clinical research and enrollment into clinical trials. L. Y. is a consultant for Veracyte, Inc. N. J. P. has participated in consulting for Olympus related to new bronchoscope developments over the past 3 years. None declared (B. T. B., M. B., A. C.).
Publisher Copyright:
© 2020 American College of Chest Physicians
PY - 2020/6
Y1 - 2020/6
N2 - Background: Bronchoscopy is commonly used to evaluate suspicious lung lesions. The yield is likely dependent on patient, radiographic, and bronchoscopic factors. Few studies have assessed these factors simultaneously while also including the preprocedure physician-assessed probability of cancer (pCA) when assessing yield. Methods: This study is a secondary data analysis from a prospective multicenter trial. Diagnostic yield of standard bronchoscopy with biopsy ± fluoroscopy, endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation, and combination bronchoscopies was assessed. Definitions for diagnostic and nondiagnostic bronchoscopies were rigorously predefined. The association of diagnostic yield with individual variables was examined by using univariate and multivariate logistic regression analyses where appropriate. Results: A total of 687 patients were included from 28 sites. Overall diagnostic yield was 69%; 80% for EBUS, 55% for bronchoscopy with biopsy ± fluoroscopy, 57% for electromagnetic navigation, and 74% for combination procedures (P <.001). Patients with larger, central lesions with adenopathy were significantly more likely to undergo a diagnostic bronchoscopy. Patients with pCA < 10% and 10% to 60% had lower yields (44% and 42%, respectively), whereas pCA > 60% yielded a positive result in 77% (P <.001). In multivariate logistic regression, the use of EBUS-TBNA, larger sized lesions, and central location were significantly associated with a diagnostic bronchoscopy. Seventeen percent of those with a malignant diagnosis and 28% of those with a benign diagnosis required secondary procedures to establish a diagnosis. Conclusions: This study is the first to assess the yield of bronchoscopy according to physician-assessed pCA in a large, prospective multicenter trial. The yield of bronchoscopy varied greatly according to physician suspicion that cancer is present, the patients’ clinical/radiographic features, and the type of procedure performed. Of the procedures performed, EBUS-TBNA was the most likely to provide a diagnosis.
AB - Background: Bronchoscopy is commonly used to evaluate suspicious lung lesions. The yield is likely dependent on patient, radiographic, and bronchoscopic factors. Few studies have assessed these factors simultaneously while also including the preprocedure physician-assessed probability of cancer (pCA) when assessing yield. Methods: This study is a secondary data analysis from a prospective multicenter trial. Diagnostic yield of standard bronchoscopy with biopsy ± fluoroscopy, endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation, and combination bronchoscopies was assessed. Definitions for diagnostic and nondiagnostic bronchoscopies were rigorously predefined. The association of diagnostic yield with individual variables was examined by using univariate and multivariate logistic regression analyses where appropriate. Results: A total of 687 patients were included from 28 sites. Overall diagnostic yield was 69%; 80% for EBUS, 55% for bronchoscopy with biopsy ± fluoroscopy, 57% for electromagnetic navigation, and 74% for combination procedures (P <.001). Patients with larger, central lesions with adenopathy were significantly more likely to undergo a diagnostic bronchoscopy. Patients with pCA < 10% and 10% to 60% had lower yields (44% and 42%, respectively), whereas pCA > 60% yielded a positive result in 77% (P <.001). In multivariate logistic regression, the use of EBUS-TBNA, larger sized lesions, and central location were significantly associated with a diagnostic bronchoscopy. Seventeen percent of those with a malignant diagnosis and 28% of those with a benign diagnosis required secondary procedures to establish a diagnosis. Conclusions: This study is the first to assess the yield of bronchoscopy according to physician-assessed pCA in a large, prospective multicenter trial. The yield of bronchoscopy varied greatly according to physician suspicion that cancer is present, the patients’ clinical/radiographic features, and the type of procedure performed. Of the procedures performed, EBUS-TBNA was the most likely to provide a diagnosis.
KW - bronchoscopy
KW - diagnostic yield
KW - lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85083185766&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2019.12.024
DO - 10.1016/j.chest.2019.12.024
M3 - Article
C2 - 31978428
AN - SCOPUS:85083185766
SN - 0012-3692
VL - 157
SP - 1656
EP - 1664
JO - CHEST
JF - CHEST
IS - 6
ER -